Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DeTACT-ASIA: Triple ACTs vs ACTs for Uncomplicated P. falciparum Malaria
NCT03939104Phase 3Completed
- Sponsor
- University of Oxford
- Start
- Jun 2021
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of amodiaquine and piperaquine in Plasmodium falciparum malaria (4 arms), sponsored by University of Oxford. Primary endpoint: PCR corrected adequate clinical and parasitological response at 42 days. Started Jun 2021; status: completed.
02
Drugs
amodiaquinepiperaquine
03
Conditions
Plasmodium falciparum malaria
Beyond the preview
Go deeper on NCT03939104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03939104.